Drugs Used in Mood Disorders Part 6 PDF
Document Details
Uploaded by leichnam
Emory & Henry College
Tags
Summary
This document details pharmacological aspects of medications used in mood disorders. It includes questions about different mechanisms of action, adverse effects, and common conditions. It appears to be lecture material or study guide.
Full Transcript
\#\#\# \*\*Slide 49: Bupropion Pharmacokinetics\*\* 1\. \*\*What is the primary enzyme responsible for the metabolism of bupropion?\*\* \- A. CYP3A4 \- B. CYP2D6 \- C. MAO-B \- D. CYP1A2 \*\*Answer:\*\* B. CYP2D6【67:0†source】 2\. \*\*Bupropion is contraindicated in patients with a history o...
\#\#\# \*\*Slide 49: Bupropion Pharmacokinetics\*\* 1\. \*\*What is the primary enzyme responsible for the metabolism of bupropion?\*\* \- A. CYP3A4 \- B. CYP2D6 \- C. MAO-B \- D. CYP1A2 \*\*Answer:\*\* B. CYP2D6【67:0†source】 2\. \*\*Bupropion is contraindicated in patients with a history of which condition?\*\* \- A. Hypertension \- B. Anxiety \- C. Seizure disorder \- D. Obesity \*\*Answer:\*\* C. Seizure disorder【67:0†source】 3\. \*\*In addition to its use in depression, bupropion is approved for which of the following conditions?\*\* \- A. Alcohol dependence \- B. Smoking cessation \- C. Migraine prevention \- D. ADHD \*\*Answer:\*\* B. Smoking cessation【67:0†source】 \-\-- \#\#\# \*\*Slide 50: New Medication: Dextromethorphan/Bupropion ER (Auvelity)\*\* 1\. \*\*What is the mechanism of action of dextromethorphan in Auvelity?\*\* \- A. NMDA receptor antagonist \- B. Serotonin reuptake inhibitor \- C. GABA receptor agonist \- D. Alpha-2 adrenergic antagonist \*\*Answer:\*\* A. NMDA receptor antagonist【67:0†source】 2\. \*\*What is a potential adverse reaction when combining dextromethorphan with other serotonergic medications?\*\* \- A. Serotonin syndrome \- B. Hypertensive crisis \- C. Bradycardia \- D. Respiratory depression \*\*Answer:\*\* A. Serotonin syndrome【67:0†source】 3\. \*\*How soon can symptom improvement begin after starting Auvelity for depression?\*\* \- A. 2 weeks \- B. 4 weeks \- C. 1 week \- D. 6 weeks \*\*Answer:\*\* C. 1 week【67:0†source】 \-\-- \#\#\# \*\*Slide 51: Trazodone (Desyrel)\*\* 1\. \*\*What receptor does trazodone antagonize that contributes to its sedative effects?\*\* \- A. Histamine H1 receptor \- B. Alpha-2 adrenergic receptor \- C. Serotonin 5-HT2A receptor \- D. GABA-A receptor \*\*Answer:\*\* A. Histamine H1 receptor【67:0†source】 2\. \*\*At low doses, trazodone is commonly used to treat which condition?\*\* \- A. Depression \- B. Anxiety \- C. Insomnia \- D. Bipolar disorder \*\*Answer:\*\* C. Insomnia【67:0†source】 3\. \*\*What is a rare but serious side effect associated with trazodone?\*\* \- A. Serotonin syndrome \- B. Priapism \- C. Hepatotoxicity \- D. Weight gain \*\*Answer:\*\* B. Priapism【67:0†source】 \-\-- \#\#\# \*\*Slide 52: Nefazodone\*\* 1\. \*\*Nefazodone is chemically related to which other antidepressant?\*\* \- A. Mirtazapine \- B. Trazodone \- C. Bupropion \- D. Sertraline \*\*Answer:\*\* B. Trazodone【67:0†source】 2\. \*\*What is a serious risk associated with nefazodone that has limited its use?\*\* \- A. Hepatotoxicity \- B. Seizures \- C. Hypertension \- D. Sexual dysfunction \*\*Answer:\*\* A. Hepatotoxicity【67:0†source】 3\. \*\*Nefazodone inhibits which enzyme, leading to significant drug interactions?\*\* \- A. CYP2D6 \- B. CYP3A4 \- C. MAO-B \- D. CYP1A2 \*\*Answer:\*\* B. CYP3A4【67:0†source】 \-\-- \#\#\# \*\*Slide 53: Mirtazapine (Remeron)\*\* 1\. \*\*What is the mechanism of action of mirtazapine?\*\* \- A. Serotonin reuptake inhibitor \- B. Alpha-2 adrenergic receptor antagonist \- C. Dopamine reuptake inhibitor \- D. GABA receptor agonist \*\*Answer:\*\* B. Alpha-2 adrenergic receptor antagonist【67:0†source】 2\. \*\*Which of the following is a common side effect of mirtazapine?\*\* \- A. Weight loss \- B. Hypertension \- C. Weight gain \- D. Sexual dysfunction \*\*Answer:\*\* C. Weight gain【67:0†source】 3\. \*\*Mirtazapine is less likely to cause which side effect compared to SSRIs?\*\* \- A. Sedation \- B. Sexual dysfunction \- C. Weight gain \- D. Dry mouth \*\*Answer:\*\* B. Sexual dysfunction【67:0†source】 \-\-- \#\#\# \*\*Slide 54: Vortioxetine (Trintellix)\*\* 1\. \*\*What is the primary mechanism of action of vortioxetine?\*\* \- A. Dopamine reuptake inhibitor \- B. Serotonin transporter (SERT) inhibitor \- C. NMDA receptor antagonist \- D. Alpha-2 adrenergic agonist \*\*Answer:\*\* B. Serotonin transporter (SERT) inhibitor【67:0†source】 2\. \*\*Which of the following receptors does vortioxetine partially agonize?\*\* \- A. 5-HT1A \- B. NMDA \- C. GABA-A \- D. Alpha-1 adrenergic \*\*Answer:\*\* A. 5-HT1A【67:0†source】 3\. \*\*Which of the following is a common side effect of vortioxetine?\*\* \- A. Diarrhea \- B. Nausea \- C. Bradycardia \- D. Weight gain \*\*Answer:\*\* B. Nausea【67:0†source】 \-\-- \#\#\# \*\*Slide 55: Vilazodone (Viibryd)\*\* 1\. \*\*Vilazodone acts as a partial agonist at which receptor?\*\* \- A. 5-HT1A receptor \- B. NMDA receptor \- C. Alpha-2 adrenergic receptor \- D. GABA-B receptor \*\*Answer:\*\* A. 5-HT1A receptor【67:0†source】 2\. \*\*What is a significant adverse effect associated with vilazodone that requires monitoring?\*\* \- A. Long QT syndrome \- B. Hypertensive crisis \- C. Weight gain \- D. Hepatotoxicity \*\*Answer:\*\* A. Long QT syndrome【67:0†source】 3\. \*\*Vilazodone's mechanism enhances serotonergic activity by inhibiting which transporter?\*\* \- A. SERT (Serotonin transporter) \- B. DAT (Dopamine transporter) \- C. NET (Norepinephrine transporter) \- D. GAT (GABA transporter) \*\*Answer:\*\* A. SERT (Serotonin transporter)【67:0†source】